PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31616924-5	2020	APOE is O-glycosylated at several sites: Thr8, Thr18, Thr194, Ser197, Thr289, Ser290, and Ser296.	peptide T amide	41-45	apolipoprotein E	Homo sapiens	0-4	
31616924-5	2020	APOE is O-glycosylated at several sites: Thr8, Thr18, Thr194, Ser197, Thr289, Ser290, and Ser296.	peptide T amide	41-44	apolipoprotein E	Homo sapiens	0-4	
31616924-5	2020	APOE is O-glycosylated at several sites: Thr8, Thr18, Thr194, Ser197, Thr289, Ser290, and Ser296.	peptide T amide	54-60	apolipoprotein E	Homo sapiens	0-4	
31616924-5	2020	APOE is O-glycosylated at several sites: Thr8, Thr18, Thr194, Ser197, Thr289, Ser290, and Ser296.	peptide T amide	47-50	apolipoprotein E	Homo sapiens	0-4	
31616924-6	2020	Plasma APOE held more abundant (20.5%) N-terminal (Thr8) sialylated core 1 (Neu5Acalpha2-3Galbeta1-3GalNAcalpha1-) glycosylation compared to CSF APOE (0.1%).	peptide T amide	51-55	apolipoprotein E	Homo sapiens	7-11	
31616924-7	2020	APOE was hinge domain glycosylated (Thr194 and Ser197) in both CSF (27.3%) and plasma (10.3%).	peptide T amide	36-42	apolipoprotein E	Homo sapiens	0-4	
31616924-8	2020	CSF APOE held almost ten-fold more abundant C-terminal (Thr289, Ser290 and Ser296) glycosylation (36.8% of CSF peptide283-299 was glycosylated, 3.8% of plasma peptide283-299), with sialylated and disialylated (Neu5Acalpha2-3Galbeta1-3(Neu5Acalpha2-6)GalNAcalpha1-) core 1 structures.	peptide T amide	56-59	apolipoprotein E	Homo sapiens	4-8